(NASDAQ: PMN) Promis Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Promis Neurosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PMN's revenue for 2028 to be $1,361,474,741, with the lowest PMN revenue forecast at $1,361,474,741, and the highest PMN revenue forecast at $1,361,474,741. On average, 1 Wall Street analysts forecast PMN's revenue for 2029 to be $5,559,355,193, with the lowest PMN revenue forecast at $5,559,355,193, and the highest PMN revenue forecast at $5,559,355,193.
In 2030, PMN is forecast to generate $10,566,453,128 in revenue, with the lowest revenue forecast at $10,566,453,128 and the highest revenue forecast at $10,566,453,128.